Foamix Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Health Care Conference

REHOVOT, Israel, and BRIDGEWATER, New Jersey, April 27, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will present a corporate overview and business update at the 42nd Annual Deutsche Bank Health Care Conference, being held on May 3-4, 2017 at The InterContinental Boston Hotel, Boston, MA.

Foamix Pharmaceuticals Presentation Details

Date:          Thursday, May 4, 2017   

Time:          12:30 pm Eastern Time

Location:     Rose Kennedy III conference room, The InterContinental Boston Hotel, Boston, MA   

Webcast:    http://edge.media-server.com/m/p/cdrrrmjh

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit http://www.foamixpharma.com.

Contact:
Dorit Hayon   
Foamix Pharmaceuticals Ltd.   
+972-8-9316233
IR@foamixpharma.com

US Investor Relations
Michael Rice
LifeSci Advisors, LLC
+1-646-597-6979
mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/foamix-pharmaceuticals-to-present-at-the-42nd-annual-deutsche-bank-health-care-conference-300447026.html

SOURCE Foamix Pharmaceuticals Ltd